Sarepta Therapeutics, Inc.
Compositions for treating muscular dystrophy

Abstract:

Improved compositions and methods for treating muscular dystrophy by administering antisense molecules capable of binding to a selected target site in the human dystrophin gene to induce exon skipping are described.